查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1419139

骨壞死治療市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按治療類型、最終用戶和地理位置

Osteonecrosis Treatment Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment Type, End User, and Geography
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

骨壞死治療市場規模預計將從2022年的6.37億美元成長到2030年的10.21億美元；預計2022年至2030年市場CAGR為6.08%。

推動市場成長的關鍵因素包括由於交通事故數量增加以及患者長期使用類固醇導致的骨壞死病例增加。此外，老年人口的增加和骨骼健康意識的增強也有利於骨壞死治療市場。然而，與手術治療相關的高成本以及與治療藥物相關的風險因素阻礙了骨壞死治療市場。

骨壞死，也稱為股骨頭缺血性壞死 (AVN)，是一種導致骨細胞死亡的疼痛性骨病變。當流向骨骼的血液受到干擾並隨著時間的推移而惡化時，就會發生這種情況。造成這種情況的原因包括骨折、髖關節脫臼、放射線治療和酗酒。

骨科損傷病例的增加和老年人口的增加推動骨壞死治療市場的成長

根據 Clevelandclinic.org 2021 年發布的統計數據，每年有 10,000-20,000 名美國人被診斷出患有缺血性壞死 (AVN)，該疾病影響所有年齡和性別的個人。近 20% 經歷髖關節脫位的人會出現 AVN。由於致命事故造成的骨骼和關節損傷數量不斷增加，全球骨壞死病例不斷增加。雖然股骨頭壞死更常見於髖部，但它也會影響肱骨、膝蓋和距骨的健康狀況。根據 StatPearls 2023 年發表的一篇文章，美國 10% 的髖關節置換術是由 AVN 造成的，其中大多數是 30-65 歲的人。髖部或膝蓋移位可能會切斷腿部的血液供應。結果，腿部組織可能無法獲得足夠的血液（一種稱為缺血的情況）並且可能死亡（一種稱為壞死的情況）。肘部或上臂骨折有時會阻礙前臂的血液流動，產生類似的併發症。當骨骼的血液供應中斷時，一部分骨骼可能會死亡，導致骨壞死。根據 PubMed Central 2022 年 1 月發表的文章，一項隊列研究涵蓋了 170,934 名嚴重創傷患者。研究結論，78.0%的外傷性髖關節脫位的重大創傷患者是在道路交通事故中受傷的，特別是機動車事故（49.9%）。

老年人更容易出現骨壞死，因為他們更容易發生骨質退化和骨折。 PubMed 於 2020 年發表的一篇文章中進行了一項研究，旨在評估空心內固定對 73 名股骨頸骨折 (FNF) 患者的長期結局的有效性，同時確定影響結局的危險因素。研究結果顯示，7人（即~10%）經歷了股骨頭壞死，4人接受了髖關節置換手術。根據世界衛生組織(WHO) 統計，到2030 年，全球每6 人中就有1 人年齡在60 歲或以上，預計60 歲以上人口將達到14 億。因此，不斷成長的老年人口和日益增強的骨骼健康意識有利骨壞死治療市場。

市場機會

生物力學解決方案的開發和正在進行的臨床試驗以推出新的創新正在創造市場機會。

用於股骨頭壞死治療的生物力學技術試圖解決關節力學和功能問題。 AVN 經常會引起骨骼結構變化，尤其是負重關節，導致不適和活動能力下降。生物力學解決方案對於保護關節功能、減輕疼痛和改善患者的生活品質至關重要。這些方法通常涉及骨科醫生、生物力學工程師和復健專家之間的多學科合作，以提供全面的護理。目前正在研究和利用各種生物力學方法來治療 AVN。這些方法包括開發專門的、可客製化的植入物，用於針對患者的特定治療，以及使用先進的成像技術進行生物力學分析，以了解改變的患者生物力學。例如，在Sage Journals 於2023 年1 月發表的一篇文章中，開展了一項研究，透過恢復9 名接受血管化骨移植和臨時橈腕跨內固定治療的患者的月骨血管供應來阻止股骨頭缺血性壞死的進展。研究得出的結論是，利用局部血管化骨移植和臨時橈腕內跨越固定提供了一種具有內部固定優點的治療選擇。

同樣，Scielo Brazil 在 2023 年 6 月發表的一篇文章中，進行了一項橫斷面研究，涵蓋了 9 名被診斷患有股骨頭壞死的患者。該研究使用 Vicon 運動捕捉系統進行患者步態分析。研究發現，股骨頭壞死的個體會採取代償步態機制來保護髖關節。這些機制包括骨盆運動增加和膝關節屈曲減少。研究也發現髖部屈曲和內收時刻減少，這可能與這些族群的肌肉無力有關。因此，生物力學分析對於評估 AVN 患者的功能很有用。這使得醫生能夠評估可顯著影響患者生活品質的日常活動。此外，它還幫助他們投資於可以改善疼痛和功能的即時非手術措施，最終帶來更好的手術結果。

此外，根據歐盟臨床試驗登記冊，7,255項臨床試驗是針對18歲以下的受試者進行的，以及年齡較大的兒科試驗的資料。根據2023 年3 月發表在MDPI 上的一篇文章，進行了一項開放標籤、非隨機、前瞻性臨床試驗，以評估間質幹細胞（MSC）治療特發性股骨頭壞死（ONFH）患者的療效. ARCO 分類中的階段低於 IIC。八名患者參與了試驗。治療前 4 週取得自體骨髓 (40 mL)，並依據良好生產規範 (GMP) 標準擴增 MSC。研究得出的結論是，使用自體間質幹細胞（MSC）對於股骨頭壞死（ONFH）患者來說是一種安全且可能有效的治療選擇。

分部概覽

「全球骨壞死治療市場」根據治療類型、最終用戶和地理位置進行細分。根據產品類型，市場分為藥物和手術。藥物細分進一步細分為非類固醇抗發炎藥、血液稀釋劑、降膽固醇藥物等。同樣，手術細分市場細分為全關節置換/全髖關節置換術（THA）、核心減壓手術、骨移植、截骨術等。藥品細分市場在2022 年佔據最大的市場佔有率。然而，預計手術細分市場複合CAGR最高可達 7.6%。

就最終用戶而言，骨壞死市場分為醫院、專科診所、門診手術中心等。預計2022年至2030年，醫院細分市場將創下市場最高CAGR。骨壞死治療涉及複雜的手術，需要特殊的醫療關注，包括診斷、治療和持續監測。醫院在為骨壞死患者提供完整的醫療服務方面發揮著至關重要的作用。根據疾病的階段和嚴重程度，他們為骨壞死提供各種治療選擇。這些治療可能包括疼痛管理、物理治療和生活方式改變等保守技術。此外，嚴重的情況下可能會進行手術治療，例如保留關節手術或關節置換手術。

目錄

第 1 章：簡介

  • 研究範圍
  • 市場定義、假設與限制
  • 市場區隔

第 2 章：執行摘要

  • 重要見解
  • 市場吸引力分析

第 3 章：研究方法

第 4 章：骨壞死治療市場格局

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈供應商名單

第 5 章：骨壞死治療市場 - 主要市場動態

  • 主要市場促進因素
  • 主要市場限制
  • 主要市場機會
  • 未來的趨勢
  • 促進因素和限制因素的影響分析

第 6 章：骨壞死治療市場 - 全球市場分析

  • 骨壞死治療 - 全球市場概覽
  • 骨壞死治療 - 全球市場與 2030 年預測

第 7 章：骨壞死治療市場 - 收入分析 - 按治療類型，2020-2030 年

  • 概述
  • 藥品
  • 手術

第 8 章：骨壞死治療市場 - 收入分析 - 按最終用戶，2020-2030 年

  • 概述
  • 醫院
  • 專科診所
  • 門診手術中心
  • 其他

第 9 章：骨壞死治療市場 - 收入分析，2020-2030 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥

註 - 將為以下提到的地區/國家提供類似的分析

  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 11 章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 12 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與專注

第 13 章：骨壞死治療市場 - 主要公司概況

  • Novartis AG

注意 - 將為以下公司列表提供類似資訊

  • 梯瓦製藥工業股份有限公司
  • 齊默比美特
  • 輝瑞公司
  • 史賽克
  • 埃克泰克公司
  • 默克公司
  • 雷迪博士實驗室有限公司
  • 維亞特里斯公司
  • 地平線治療公司

第 14 章：附錄

  • 詞彙表
  • 關於 Insight Partners
  • 市場情報雲
簡介目錄
Product Code: TIPRE00033413

The osteonecrosis treatment market size is expected to grow from US$ 637 million in 2022 to US$ 1,021 million by 2030; the market is estimated to register a CAGR of 6.08% from 2022 to 2030.

Key factors driving the market growth include the rising cases of osteonecrosis in people owing to an increasing number of road accidents and long-term use of steroids among patients. Additionally, the rising geriatric population and growing awareness about bone health benefit the osteonecrosis treatment market. However, the high cost associated with surgical treatments and the risk factors associated with treatment drugs hamper the osteonecrosis treatment market.

Osteonecrosis, also known as avascular necrosis (AVN), is a painful bone disease that results in the death of bone cells. It happens when blood flow to bones is disrupted and worsens over time. The causes of this condition include broken bones, dislocated hips, radiation therapy, and alcohol abuse.

Rising Cases of Orthopedic Injuries and Increasing Geriatric Population Drive Osteonecrosis Treatment Market Growth

According to statistics published by Clevelandclinic.org in 2021, 10,000-20,000 Americans are diagnosed with avascular necrosis (AVN) annually, with the condition affecting individuals of all ages and genders. Nearly 20% of people who experience hip dislocation develop AVN. The cases of osteonecrosis are rising globally owing to the increasing number of bone and joint injuries caused by fatal accidents. Although osteonecrosis more commonly affects the hip, it can also hamper the condition of the humerus, knee, and talus. As per an article published by StatPearls in 2023, AVN causes 10% of hip arthroplasties in the US, mostly in people aged 30-65. A displaced hip or knee might cut off blood supply to the leg. As a result, the tissues in the leg may not receive enough blood (a condition known as ischemia) and may die (a condition known as necrosis). Elbow or upper arm fractures can occasionally impede blood flow to the forearm, creating similar complications. When blood supply to a bone is interrupted, a portion of the bone may die, causing osteonecrosis. As per the article published by PubMed Central in January 2022, a cohort study included 170,934 major trauma patients. The study concluded that 78.0% of the major trauma patients with traumatic hip dislocations were injured in road traffic accidents, particularly in motor vehicle accidents (49.9%).

Older people are more likely to experience osteonecrosis as they are more prone to bone degeneration and fractures. In an article published by PubMed in 2020, a study was carried out to assess the effectiveness of cannulated internal fixation in long-term outcomes in 73 patients with femoral neck fracture (FNF), alongside identifying the risk factors affecting outcomes. The study results showed that 7 (i.e., ~10%) experienced femoral head necrosis, and 4 underwent hip replacement. According to the World Health Organization (WHO), 1 in 6 people worldwide will be aged 60 years or over by 2030, with an estimated 1.4 billion people over 60. Therefore, the burgeoning geriatric population and growing awareness about bone health favor the osteonecrosis treatment market.

Market Opportunity

Development of Biomechanical Solutions and Ongoing Clinical Trials to Launch New Innovations Are Creating Opportunities in the Market.

Biomechanical techniques for avascular necrosis therapy attempt to solve joint mechanics and functioning concerns. AVN frequently causes structural changes in bone, particularly in weight-bearing joints, resulting in discomfort and decreased mobility. Biomechanical solutions are vital in preserving joint function, reducing pain, and improving a patient's quality of life. These approaches often involve a multidisciplinary collaboration between orthopedic surgeons, biomechanical engineers, and rehabilitation specialists to provide comprehensive care. Various biomechanical approaches are currently being studied and utilized as a treatment for AVN. These approaches include developing specialized and customizable implants for patient-specific treatments and biomechanical analysis using advanced imaging to understand altered patient biomechanics. For instance, in an article published by Sage Journals in January 2023, a study was carried out to stop the advancement of avascular necrosis by restoring lunate vascularity in nine patients who were treated with vascularized bone grafts and interim radiocarpal spanning internal fixation. The study concluded that utilizing a local vascularized bone graft with temporary internal radiocarpal spanning fixation provides a therapeutic option with the advantages of internal immobilization.

Similarly, in an article published by Scielo Brazil in June 2023, a cross-sectional study included nine patients diagnosed with osteonecrosis of the femoral head. The study used Vicon Motion Capture Systems for patients' gait analysis. The study found that individuals with osteonecrosis of the femoral head adopt compensatory gait mechanisms to protect their hip joints. These mechanisms include increased pelvic motion and decreased knee flexion. The study also identified decreased moments for hip flexion and adduction, which may be related to muscle weakness in these groups. Therefore, biomechanical analysis is useful for evaluating the functionality of patients with AVN. This allows physicians to assess daily activities that can significantly affect patients' quality of life. Additionally, it helps them invest in immediate non-operative measures that can improve pain and functionality, eventually leading to better surgical outcomes.

Moreover, according to the European Union Clinical Trials Register, 7255 clinical trials were conducted with subjects under 18 years old, and data on older pediatric trials. According to an article published on MDPI in March 2023, an open-label, non-randomized, prospective clinical trial was conducted to evaluate the efficacy of mesenchymal stem cells (MSCs) in treating idiopathic osteonecrosis of the femoral head (ONFH) in patients with stage less than IIC in the ARCO classification. Eight patients were included in the trial. Autologous bone marrow (40 mL) was obtained four weeks before therapy, and MSCs were expanded under Good Manufacturing Practice (GMP) standards. The study concluded that using autologous mesenchymal stem cells (MSCs) is a safe and potentially effective treatment option for patients with femoral head osteonecrosis (ONFH).

SEGMENTAL OVERVIEW

The "Global Osteonecrosis Treatment Market" is segmented based on treatment type, end user, and geography. Based on product type, the market is bifurcated into drugs and surgeries. Drug segments are further segmented into NSAIDs, blood thinners, cholesterol-lowering drugs, and others. Similarly, the surgeries segment is sub-segmented into total joint replacement/ total hip arthroplasty (THA), core decompression surgery, bone graft, osteotomy, etc. The drugs segment held the largest market share in 2022. However, the surgeries segment is anticipated to grow with the highest CAGR of 7.6%.

In terms of end users, the osteonecrosis market is segmented into hospitals, specialty clinics, ambulatory surgical centers, and others. The hospital segment is expected to record the highest CAGR in the market from 2022 to 2030. Osteonecrosis treatment involves complicated surgeries that need special medical attention, including diagnosis, treatment, and continuous monitoring. Hospitals play an essential role in delivering complete healthcare services to osteonecrosis patients. Depending on the disease's stage and severity, they provide various treatment options for osteonecrosis. Conservative techniques such as pain management, physical therapy, and lifestyle changes may be included in these treatments. Furthermore, surgical therapies such as joint-preserving operations or joint replacement surgeries may be undertaken in severe cases.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Osteonecrosis Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Osteonecrosis Treatment Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Osteonecrosis Treatment Market - Global Market Analysis

  • 6.1 Osteonecrosis Treatment - Global Market Overview
  • 6.2 Osteonecrosis Treatment - Global Market and Forecast to 2030

7. Osteonecrosis Treatment Market - Revenue Analysis (USD Million) - By Treatment Type, 2020-2030

  • 7.1 Overview
  • 7.2 Drugs
    • 7.2.1 Nonsteroidal Anti-Inflammatory Drugs
    • 7.2.2 Blood Thinners
    • 7.2.3 Cholesterol-Lowering Drugs
    • 7.2.4 Others
  • 7.3 Surgery
    • 7.3.1 Core Decompression Surgery
    • 7.3.2 Osteotomy
    • 7.3.3 Bone Graft
    • 7.3.4 Total joint replacement
    • 7.3.5 Others

8. Osteonecrosis Treatment Market - Revenue Analysis (USD Million) - By End User, 2020-2030

  • 8.1 Overview
  • 8.2 Hospitals
  • 8.3 Specialty Clinics
  • 8.4 Ambulatory Surgical Centers
  • 8.5 Others

9. Osteonecrosis Treatment Market -Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Osteonecrosis Treatment Market Overview
    • 9.1.2 North America Osteonecrosis Treatment Market Revenue and Forecasts to 2030
    • 9.1.3 North America Osteonecrosis Treatment Market Revenue and Forecasts and Analysis - By Treatment Type
    • 9.1.4 North America Osteonecrosis Treatment Market Revenue and Forecasts and Analysis - By End User
    • 9.1.5 North America Osteonecrosis Treatment Market Revenue and Forecasts and Analysis - By Countries
      • 9.1.5.1 United States Osteonecrosis Treatment Market
        • 9.1.5.1.1 United States Osteonecrosis Treatment Market, by Treatment Type
        • 9.1.5.1.2 United States Osteonecrosis Treatment Market, by End User
      • 9.1.5.2 Canada Osteonecrosis Treatment Market
        • 9.1.5.2.1 Canada Osteonecrosis Treatment Market, by Treatment Type
        • 9.1.5.2.2 Canada Osteonecrosis Treatment Market, by End User
      • 9.1.5.3 Mexico Osteonecrosis Treatment Market
        • 9.1.5.3.1 Mexico Osteonecrosis Treatment Market, by Treatment Type
        • 9.1.5.3.2 Mexico Osteonecrosis Treatment Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 France
    • 9.2.3 Italy
    • 9.2.4 Spain
    • 9.2.5 United Kingdom
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 Australia
    • 9.3.2 China
    • 9.3.3 India
    • 9.3.4 Japan
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 Middle East and Africa
    • 9.4.1 South Africa
    • 9.4.2 Saudi Arabia
    • 9.4.3 U.A.E
    • 9.4.4 Rest of Middle East and Africa
  • 9.5 South and Central America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
    • 9.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Osteonecrosis Treatment Market - Key Company Profiles

  • 13.1 Novartis AG
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 13.2 Teva Pharmaceutical Industries Ltd.
  • 13.3 Zimmer Biomet
  • 13.4 Pfizer Inc
  • 13.5 Stryker
  • 13.6 Exactech Inc
  • 13.7 Merck Co Inc
  • 13.8 Dr Reddy's Laboratories Ltd.
  • 13.9 Viatris Inc
  • 13.10 Horizon Therapeutics plc

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud